Basic Information
VANCONEX LYOPHILIZED POWDER FOR INJECTION 500MG/VIAL
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Regulatory Information
SIN16014P
September 24, 2020
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XJ01XA01
Company Information
Active Ingredients
Strength: 500 mg/vial
Detailed Information
Contraindications
**CONTRAINDICATIONS** Vancomycin Hydrochloride for Injection is contraindicated in patients with known hypersensitivity to this antibiotic.
Indication Information
**INDICATIONS** Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin's effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.